Assistant Professor, Hematology and Oncology, Baylor College of Medicine
Oncology
Dr. Anita Sabichi, MD
|
|
Give Review
Anita Sabichi, MD is an expert in the field of Oncology. She researched medicine at University of Colorado Denver School of Medicine. University of Colorado Denver School of Medicine is a top medical university. University of Colorado Denver School of Medicine is ranked 35 in research and 8 in primary care medicine She has 2 awards "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Dr. Anita Sabichi is a published doctor and has 59 publications published. The lastest was: 'Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin.' She accepts all Medicare patients.
Publications
- HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer.
- Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.
- Induction of programmed Cell death in Kaposi's sarcoma Cells by preparations of human chorionic gonadotropin.
- Retinoids in the chemoprevention of bladder Cancer.
- Cancer chemoprevention: progress and promise.
- Retinoic acid receptor beta expression and growth inhibition of gynecologic Cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.
- Molecular characterization of adenoCarcinoma of the cervix.
- Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies.
- Regulation of nuclear oncogenes expressed in lung Cancer cell lines.
- The molecular biology of lung Cancer: application to early detection and prevention.
- Sensory control of the initiation of hatching in chicks: effects of a local anesthetic injected into the neck.
- Neural control of limb coordination. I. Comparison of hatching and walking motor output patterns in normal and deafferented chicks.
- Chemoprevention of superficial bladder Cancer.
- Effects of novel phenylretinamides on cell growth and apoptosis in bladder Cancer.
- Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate Cells.
- Selenium effects on prostate Cell growth.
- cJun overexpression in MCF-7 breast Cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.
- Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder Cancer.
- RARbeta1': primed to fight retinoid resistance in Lung carcinogenesis.
- Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate Cancer.
- Suppression of prostate tumor cell growth by stromal cell prostaGlandin D synthase-derived products.
- Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia.
- Transitional Cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression.
- Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate Cells.
- Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate Cells.
- Focus on bladder Cancer.
- COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary Cancer.
- Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.
- Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
- The use of short tandem repeat profiling to characterize human bladder Cancer cell lines.
- High-dose fenretinide in Oral leukoplakia.
- Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial Cells.
- Clinical model of cost of bladder Cancer in the elderly.
- Analysis of the expression of biomarkers in urinary bladder Cancer using a tissue microarray.
- Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder Cancer.
- Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous Cell carcinoma.
- Clinical model of lifetime cost of treating bladder Cancer and associated complications.
- Frontiers in Cancer prevention research.
- Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous Cell carcinoma of the bladder.
- Centrosomal abnormality is common in and a potential biomarker for bladder Cancer.
- Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
- COX-2 inhibitors and other NSAIDs in bladder and prostate Cancer.
- A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer.
- System level changes in gene expression in maturing Bladder mucosa.
- Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells.
- American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for trea...
- Identification of genes correlated with early-stage bladder Cancer progression.
- Mortality in the randomized, controlled Lung intergroup trial of isotretinoin.
- 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activa...
- Selenium accumulation in Prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.
- Characterization of a panel of Cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene trans...
- Three synchronous HPV-associated squamous cell carcinomas of Waldeyer's ring: case report and comparison with Slaughter's model of field Cancerization.
- Identification of cJun-responsive genes in Rat-1a Cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independen...
- Comparative outcomes of bladder Cancer.
- The risk of second primary tumors after resection of stage I nonsmall cell lung Cancer.
- Interobserver reproducibility of the Lagios nuclear grading system for ductal Carcinoma in situ.
- Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression.
- Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene.
Schools
Univ Of Co Sch Of Med
Ny and Presby Hp Columbia Campus
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
National Institutes of Health Clinical Center -
New York Presbyterian Hospital - Columbia Campus -
University of Colorado Denver School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center -
Baylor St. Luke's Medical Center -
Michael E. DeBakey Veterans Affairs Medical Center
Drug Facts
| NPI NUMBER | 1255486924 | |
| NPPES Provider LastName | SABICHI | |
| NPPES Provider FirstName | ANITA | |
| NPPES Provider ZIPCode | 770303411 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 233.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 50.0 | |
| Percent Opioid Claims | 21.46 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255486924 |
| Last Name Of The Provider | SABICHI |
| First Name Of The Provider | ANITA |
| View All |
Similar Doctors
|
|
Dr. Fredrick B. Hagemeister, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Craig A. Kovitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph A. Ludwig IV, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Henry J. Conter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edmund S. Kopetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John O. Mendelsohn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shan Guo, MD
This Doctor is OpenDoctor Recommended.
|